Orasis Highlights First-Year Qlosi Uptake and Safety Indicators

According to a recent LinkedIn post from Orasis Pharmaceuticals, the company is marking the one-year anniversary of the U.S. launch of Qlosi, its eye-drop treatment for presbyopia. The post highlights commentary from President and COO Paul Smith, who reflects on product performance and patient impact during this initial commercialization period.

The post indicates that Qlosi refill rates are running at roughly double those seen in established ophthalmic segments for chronic conditions, suggesting early signs of durable patient use and potentially recurring revenue. It also notes that reported adverse events remain in the single-digit percentage range, which, if sustained, could support physician confidence and lower barriers to broader adoption.

Orasis further points to data from the Bascom Palmer Eye Institute that it says confirm a pupil-selective mechanism of action for Qlosi. This characterization may help differentiate the product in a competitive presbyopia treatment landscape, where safety profile, tolerability, and mechanism are key prescribing considerations for eye-care professionals.

For investors, the emphasis on refill behavior, tolerability metrics, and mechanistic validation suggests Orasis is positioning Qlosi as a scalable, chronic-use product rather than a one-time trial therapy. If these trends persist and convert into broader market penetration, the franchise could support revenue growth and enhance the company’s standing within the ophthalmic therapeutics segment.